Eliza Slawther
Senior Writer
Eliza began reporting on health and medical science in 2018 while completing her Master’s degree in Journalism at City, University of London. During her degree program she interned at C+D and on the London Evening Standard’s health desk. In the years since, Eliza has written about everything from mid-stage drug development to market access for medicines and devices in the EU and beyond. Her work explores the trials and tribulations of securing reimbursement for medical products in Europe, and Eliza is particularly interested in the challenges of funding innovation in health care.
Eliza has lived in London since 2017 and is originally from Cheshire, in the north west of England. She has a BA in English Literature from the University of Manchester and is in the process of completing a second undergraduate degree in Biomedicine from Birkbeck College, an evening university that is part of the University of London.
Latest From Eliza Slawther
Pharma Industry Has Shown ‘Huge Interest’ In AI For Drug Development, Says EMA
The EMA received more than 1,000 responses to its draft reflection paper on AI in drug development, some of which will be incorporated into the final document, an agency representative told this week’s RAPS Euro Convergence 2024.
Not-For-Profit Models Needed For Commercially Unviable Rare Disease Drugs
Developing drugs for some rare diseases is “just not commercially feasible,” meaning that alternative approaches, such as funding through venture philanthropy and not-for-profit models, need to be explored, a gene therapy professor has said.
Shionogi: Other Countries Must Follow UK’s Lead On Antimicrobial Incentives
Shionogi’s UK general manager praised NHS England’s novel subscription model for antibiotics, but warned the country would be “wasting money” unless other global regulators introduced similar incentives for antimicrobial development.
UK’s MHRA To Use AI In Regulatory Review Process & RWD Analysis
The MHRA’s regulatory strategy on AI outlines key areas where this technology could be used to improve the agency’s own processes, and says that the use of AI to develop drugs will not change the questions it asks companies.
‘Shocking’ MHRA Performance & Poor Data Transparency Blamed For UK’s Clinical Trial Crisis
While the UK’s drug regulator, the MHRA, has “pulled its socks up massively” in recent months, its poor performance was highlighted as a top cause of the UK’s faltering clinical trials ecosystem by a former health minister.
MHRA Needs ‘Rebuilding’ After Post-Brexit Loss Of Capacity And Industry Investment
The UK’s drug regulator, the MHRA, has taken a hit in terms of capacity and funding post-Brexit, and could benefit from government backing to rebuild its regulatory capacity, a leading venture capitalist has said.